Amarin Corp Plcuk (AMRN) Research & Development (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Research & Development of $1.5 million for Q1 2026, down 25.51% year-over-year from $2.0 million in Q1 2025, and down 71.68% quarter-over-quarter from $5.4 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Research & Development (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Research & Development data on file, last reported at $1.5 million in Q1 2026.
- Research & Development for Q1 2026 came in at $1.5 million, down 25.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 million (up 715.95% YoY), and the FY2025 annual result was $19.8 million, up 139.32% from the prior year.
- Research & Development declined to $1.5 million in Q1 2026 per AMRN's latest filing, from $5.4 million in the prior quarter.
- Over five years, Research & Development peaked at $10.1 million in Q1 2022 and troughed at -$7.4 million in Q4 2022.
- A 5-year average of $2.8 million and a median of $4.9 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development sank 228.73% in 2022, then surged 181.28% in 2025.
- A 5-year view of Research & Development shows it stood at -$7.4 million in 2022, then rose by 3.35% to -$7.2 million in 2023, then advanced by 7.68% to -$6.6 million in 2024, then soared by 181.28% to $5.4 million in 2025, then sank by 71.68% to $1.5 million in 2026.
- Business Quant data shows AMRN's Research & Development at $1.5 million in Q1 2026, $5.4 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -2.28 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 3.51 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 3.53 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 2.47 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.65 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 1.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.52 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Sep 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 4.92 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | -6.61 Mn |
| Sep 30, 2024 | 1.43 Mn |
| Jun 30, 2024 | 4.75 Mn |
| Mar 31, 2024 | 5.60 Mn |
| Dec 31, 2023 | -7.16 Mn |
| Sep 30, 2023 | 5.11 Mn |
| Jun 30, 2023 | 5.64 Mn |
| Mar 31, 2023 | 5.68 Mn |
| Dec 31, 2022 | -7.41 Mn |
| Sep 30, 2022 | 5.77 Mn |
| Jun 30, 2022 | 9.36 Mn |
| Mar 31, 2022 | 10.05 Mn |
| Dec 31, 2021 | 5.75 Mn |
| Sep 30, 2021 | 7.82 Mn |
| Jun 30, 2021 | 6.36 Mn |